15-Sept-2026 14:14:41
SUDARSHANAcquisition and merger
SUDARSHAN PHARMA: US STEP-DOWN SUBSIDIARY ACQUIRES 9.50% EQUITY SHARES OF MED THERAPY BIOTECHNOLOGY INC.
• Proposal to acquire 9.50% equity shares of Med Therapy Biotechnology Inc., USA is under due diligence. • Confirmation from Med Therapy Board of Directors decision and resolution is pending. • Proposal to acquire 1.50% equity shares each by Mr. Hemal Mehta and Mr. Sachin Mehta is also under due diligence. • Confirmation from Med Therapy Board of Directors decision and resolution is pending. Impact: Neutral (Disclosure of pending due diligence and board resolutions for share acquisition)
Sudarshan Pharma Industries Ltd
Open attachment